Recent advancements in bio-nanotechnology have enabled the development of a light-reaction enriched thylakoid NADPH-foundry, termed LEAF. By extracting functional grana superstructures from plant chloroplasts and re-encapsulating them with Pluronic F127, researchers have created a nanosized, autonomous system capable of generating NADPH via light-dependent photosynthetic reactions. Unlike endogenous mammalian pathways, LEAF functions independently of metabolic control, providing a robust, orthogonal source of reducing power.

In the context of keratoconjunctivitis sicca (KS), LEAF offers a promising therapeutic strategy to address chronic inflammation and oxidative stress. By utilizing ambient visible light, LEAF restores intracellular and extracellular redox homeostasis, effectively suppressing inflammatory crosstalk between corneal epithelial cells and macrophages. This approach bypasses the limitations of traditional anti-inflammatory agents, such as delayed onset or localized irritation, representing a significant step toward conferring mammalian tissues with targeted, light-driven metabolic support to counteract degenerative pathologies.

The US Trade Representative (USTR) has initiated a Section 301 investigation into Germany’s pharmaceutical pricing policies, citing concerns that US patients bear a disproportionate burden of global research and development (R&D) costs. USTR Ambassador Jamieson Greer stated that the probe follows Germany's proposal of legislative measures aimed at reducing healthcare spending, which the US views as a barrier to equitable global innovation funding.

Germany’s draft legislation, intended to address a significant deficit in state insurance funds, has faced strong opposition from industry leaders, including Eli Lilly and Boehringer Ingelheim. While some contentious elements of the proposal have been retracted, the US government maintains that these policies unfairly impact American R&D contributions. Potential outcomes of the investigation, scheduled for a public hearing on September 22, could include mandates for supplemental discounts or variable rate rebates, with officials advocating for a model similar to the U.K.’s recent agreement on pharmaceutical pricing.

For 20 years, Prix Galien USA has honored the breakthroughs shaping the future of healthcare and improving lives worldwide. Often regarded by the industry as the equivalent of the Nobel Prize of biopharmaceutical research, this is where innovation meets impact.

From groundbreaking therapies to life-saving technologies, this is more than an event, it’s a global movement advancing human health.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations leading up to the event.

Bayer has successfully deployed its self-supervised foundation model for digital histopathology on AMD Instinct™ GPU accelerators, marking a critical milestone in scaling pharmaceutical R&D infrastructure. In collaboration with AMD Silo AI™, the project moved Bayer’s DINOv2-based training pipeline onto AMD hardware, achieving improved throughput compared to the company’s existing high-performance computing (HPC) environment.

The deployment demonstrated the maturity of the AMD ROCm™ software stack, which required no code modifications for the build environment. Through iterative co-development, the teams optimized training recipes for AMD Instinct MI300X and MI355X GPUs. Key performance enhancements were realized through memory-efficient attention mechanisms via xFormers and the precise alignment of parallelism strategies with Bayer’s model architecture and cluster topology. This partnership provides a validated, high-throughput pathway for Bayer to iterate on large-scale histopathology models, ensuring reliable and reproducible performance for complex, data-intensive research workflows.

Bulgaria’s government has launched a comprehensive review of its national medicines policy, aiming to dismantle market overregulation and address inefficiencies in high-cost therapy procurement. Deputy Health Minister Petar Salchev identified significant price disparities in state-hospital purchases of unauthorized medicines, a byproduct of a policy that mandates purchasing at the lowest EU price. While intended to control costs, this approach has historically discouraged manufacturers from registering innovative therapies in the country.

Industry stakeholders, including ARPharM Bulgaria, contend that improving access requires shifting away from aggressive price-minimum mandates and reducing burdensome rebate requirements. These policies are currently driving a critical delay in new drug launches, with many companies signaling potential market withdrawal. Balancing these reforms remains challenging for the Radev administration, which faces significant fiscal constraints, including rising budget deficits and over €400 million in outstanding debts held by state-owned hospitals.

While many people have heard of the placebo effect, its lesser-known twin – the nocebo effect – may be quietly killing clinical trials.

The nocebo effect is a phenomenon where a person experiences adverse outcomes to a medical treatment that cannot be explained by the pharmacological effects of the treatment1. These can be triggered by verbal suggestions (from both clinicians and other patients), media reports, or through written patient information2. While relatively common in clinical trials, the nocebo effect is rarely discussed and often not taken into account when interpreting trial results2.

The evidence is compelling. In a trial examining the nocebo effect in antidepressant use, over 60% of individuals in the placebo group reported treatment-emergent adverse effects, with nearly 5% dropping out of the trial3. A different study, investigating the prevalence of sexual side effects on finasteride treatment, split participants into two groups: one counselled on the drug’s sexual side effects and one not4. Over 40% of the counselled group reported sexual side effects, compared to only 15% of those who weren’t told to expect them. Consequently, clinician-conveyed information produced measurable, real-world harm to patients, and had a detrimental effect on clinical trials.

The implications for drug development are serious, but often unexamined. Nocebo-inflated adverse event reports may contribute to increased trial dropout, distorted safety conclusions, and may prevent continued investigation of a promising drug. There is not currently any direct evidence that drugs have been abandoned due to the nocebo effect – partly due to limited investigation of failed compounds – but given that ~90% of drugs are failing clinical trials, and tolerability is a common cause, we must ask ourselves: how many nocebo casualties are we misclassifying as pharmacological ones?

Informed consent is non-negotiable, but reevaluating the framing, language, and delivery behind conveying side effect information may significantly affect clinical trials and patient outcomes.

References

1. Colloca L. The Nocebo Effect. Annu Rev Pharmacol Toxicol. 2024;64:171-190. doi:10.1146/annurev-pharmtox-022723-112425

2. Wartolowska K. The nocebo effect as a source of bias in the assessment of treatment effects. F1000Res. 2019;8:5. doi:10.12688/f1000research.17611.2

3. Dodd S, Schacht A, Kelin K, et al. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry. 2015;76(6):702-711. doi:10.4088/JCP.13r08858

4. Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5  mg and Sexual Side Effects: How Many of these are Related to a Nocebo Phenomenon? The Journal of Sexual Medicine. 2007;4(6):1708-1712. doi:10.1111/j.1743-6109.2007.00563.x